Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
ValiRx plc ( (GB:VAL) ) has provided an announcement.
ValiRx plc has launched a retail share offer via Winterflood’s Retail Access Platform to raise up to £150,000 by issuing up to 75,000,000 new ordinary shares at 0.2 pence each, matching the price used in a recently completed £1.005 million placing and subscription. Retail investors who participate are to receive one warrant per share, exercisable at 0.28 pence for three years, subject to shareholder approval at the upcoming annual general meeting.
The move extends participation in the fundraise to UK retail shareholders alongside institutional investors, with CEO Mark Eccleston indicating an intention to subscribe for 25,000,000 shares, signalling management confidence in the strategy. The proceeds from the retail offer will be used in the same way as the institutional placing funds, strengthening ValiRx’s capital base for its early-stage pipeline, although completion is contingent on AIM admission and, for warrants and broker warrants, on securing sufficient shareholder allotment authorities.
Spark’s Take on VAL Stock
According to Spark, TipRanks’ AI Analyst, VAL is a Neutral.
ValiRx plc’s overall stock score is primarily impacted by its challenging financial performance, characterized by significant losses and reliance on external financing. The technical analysis suggests a bearish trend, with some potential for upward movement. The valuation is unattractive due to a negative P/E ratio and lack of dividend yield.
To see Spark’s full report on VAL stock, click here.
More about ValiRx plc
ValiRx plc is an AIM-quoted life sciences company specialising in early-stage cancer therapeutics and women’s health, with a development pipeline that includes assets such as CLX001 and VAL201. The company focuses on advancing innovative treatments in oncology and related indications, positioning itself within the high-risk, high-reward segment of preclinical and early clinical drug development.
Average Trading Volume: 4,512,309
Technical Sentiment Signal: Strong Sell
Current Market Cap: £1.49M
For an in-depth examination of VAL stock, go to TipRanks’ Overview page.